Drug intelligence / Profile preview

acebutolol

Development stage: Approved
Lead developer: AkzoNobel
Modality: Small Molecules
Administration: Oral

Overview

Acebutolol is a cardioselective beta-1 blocker medication with intrinsic sympathomimetic activity (ISA). It works by blocking beta-1 receptors in the heart, slowing heart rate and decreasing blood pressure. Unlike many beta blockers, it provides low-grade beta stimulation at rest while acting as a typical beta-blocker when sympathetic activity is high. This results in smaller decreases in heart rate and cardiac output compared to beta blockers without this property. It has minimal impact on serum lipids and does not decrease HDL cholesterol levels.

Brand names: Sectral

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on acebutolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acebutolol.

Explore the full profile